TransMedics Group Inc. Receives FDA Approval to Launch Next-Generation OCS Heart Trial

Reuters

Aug 04

<a href="https://laohu8.com/S/TMDX">TransMedics Group Inc.</a> Receives FDA Approval to Launch Next-Generation OCS Heart Trial

TransMedics Group Inc., a medical technology company specializing in organ transplant therapy, announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption $(IDE)$. This approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial. The trial is a two-part clinical study aimed at demonstrating the benefits of prolonged heart perfusion using the OCS™ Heart System and comparing its effectiveness in donation after brain death $(DBD)$ cases to traditional static cold storage methods. With a sample size expected to exceed 650 patients, this trial is set to be the largest heart preservation for transplant trial ever conducted worldwide. This milestone marks a significant step in TransMedics' efforts to transform the standard of care in cardiothoracic transplants.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43286) on August 04, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2556238923"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556238923\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556238923?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556238923","market":"fut","top_or_hot":-1,"title":"TransMedics Group Inc. Receives FDA Approval to Launch Next-Generation OCS Heart Trial","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TMDX\">TransMedics Group Inc.</a> Receives FDA Approval to Launch Next-Generation OCS Heart Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransMedics Group Inc., a medical technology company specializing in organ transplant therapy, announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption <a href=\"https://laohu8.com/S/IDE\">$(IDE)$</a>. This approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial. The trial is a two-part clinical study aimed at demonstrating the benefits of prolonged heart perfusion using the OCS™ Heart System and comparing its effectiveness in donation after brain death <a href=\"https://laohu8.com/S/DBD\">$(DBD)$</a> cases to traditional static cold storage methods. With a sample size expected to exceed 650 patients, this trial is set to be the largest heart preservation for transplant trial ever conducted worldwide. This milestone marks a significant step in TransMedics' efforts to transform the standard of care in cardiothoracic transplants.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43286) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TransMedics Group Inc. Receives FDA Approval to Launch Next-Generation OCS Heart Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTransMedics Group Inc. Receives FDA Approval to Launch Next-Generation OCS Heart Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TMDX\">TransMedics Group Inc.</a> Receives FDA Approval to Launch Next-Generation OCS Heart Trial\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        TransMedics Group Inc., a medical technology company specializing in organ transplant therapy, announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption <a href=\"https://laohu8.com/S/IDE\">$(IDE)$</a>. This approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial. The trial is a two-part clinical study aimed at demonstrating the benefits of prolonged heart perfusion using the OCS™ Heart System and comparing its effectiveness in donation after brain death <a href=\"https://laohu8.com/S/DBD\">$(DBD)$</a> cases to traditional static cold storage methods. With a sample size expected to exceed 650 patients, this trial is set to be the largest heart preservation for transplant trial ever conducted worldwide. This milestone marks a significant step in TransMedics' efforts to transform the standard of care in cardiothoracic transplants.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43286) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL2kj9SD:1","article_id":"2556238923","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556238923","pubTimestamp":1754308933,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"TransMedics Group Inc., a medical technology company specializing in organ transplant therapy, announced that it has received conditional approval from the U.S. Food and Drug Administration  for its Investigational Device Exemption . This approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial. The trial is a two-part clinical study aimed at demonstrating the benefits of prolonged heart perfusion using the OCS Heart System and comparing its effectiveness in donation after brain death  cases to traditional static cold storage methods. With a sample size expected to exceed 650 patients, this trial is set to be the largest heart preservation for transplant trial ever conducted worldwide. This milestone marks a significant step in TransMedics' efforts to transform the standard of care in cardiothoracic transplants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4585":"ETF&股票定投概念","TMDX":"TransMedics Group Inc.","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"TransMedics Group Inc.获得FDA批准启动下一代OCS心脏试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TMDX":0.9},"content_text":"TransMedics Group Inc. Receives FDA Approval to Launch Next-Generation OCS Heart Trial\n    \n\n        TransMedics Group Inc., a medical technology company specializing in organ transplant therapy, announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) for its Investigational Device Exemption $(IDE)$. This approval allows TransMedics to initiate its Next-Generation OCS ENHANCE Heart trial. The trial is a two-part clinical study aimed at demonstrating the benefits of prolonged heart perfusion using the OCS™ Heart System and comparing its effectiveness in donation after brain death $(DBD)$ cases to traditional static cold storage methods. With a sample size expected to exceed 650 patients, this trial is set to be the largest heart preservation for transplant trial ever conducted worldwide. This milestone marks a significant step in TransMedics' efforts to transform the standard of care in cardiothoracic transplants.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transmedics Group Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE43286) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}